IMODIUM A-D Drug Patent Profile

Which patents cover Imodium A-d, and what generic alternatives are available?

Imodium A-d is a drug marketed by Kenvue Brands and J And J Consumer Inc and is included in three NDAs.

The generic ingredient in IMODIUM A-D is loperamide hydrochloride. There are eleven drug master file entries for this compound. One hundred and two suppliers are listed for this compound. Additional details are available on the loperamide hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Imodium A-d

A generic version of IMODIUM A-D was approved as loperamide hydrochloride by MYLAN on September 18^th, 1991.

Summary for IMODIUM A-D

US Patents:	0
Applicants:	2
NDAs:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	101
Clinical Trials:	25
Patent Applications:	3,824
What excipients (inactive ingredients) are in IMODIUM A-D?	IMODIUM A-D excipients list
DailyMed Link:	IMODIUM A-D at DailyMed

See drug sales revenues for IMODIUM A-D

Recent Clinical Trials for IMODIUM A-D

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Gilead Sciences	Phase 2
MedSIR	Phase 2
Naia Pharmaceuticals	Phase 1/Phase 2

See all IMODIUM A-D clinical trials

Pharmacology for IMODIUM A-D

Drug Class	Opioid Agonist
Mechanism of Action	Opioid Agonists

US Patents and Regulatory Information for IMODIUM A-D

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Kenvue Brands	IMODIUM A-D	loperamide hydrochloride	SOLUTION;ORAL	019487-001	Mar 1, 1988		DISCN	Yes	No
J And J Consumer Inc	IMODIUM A-D EZ CHEWS	loperamide hydrochloride	TABLET, CHEWABLE;ORAL	020448-001	Jul 24, 1997		DISCN	Yes	No
Kenvue Brands	IMODIUM A-D	loperamide hydrochloride	SOLUTION;ORAL	019487-002	Jul 8, 2004		OTC	Yes	Yes
Kenvue Brands	IMODIUM A-D	loperamide hydrochloride	TABLET;ORAL	019860-001	Nov 22, 1989		OTC	Yes	Yes

Expired US Patents for IMODIUM A-D

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Kenvue Brands	IMODIUM A-D	loperamide hydrochloride	SOLUTION;ORAL	019487-001	Mar 1, 1988	3,714,159

International Patents for IMODIUM A-D

See the table below for patents covering IMODIUM A-D around the world.

Country	Patent Number	Title	Estimated Expiration
Israel	36949	SUBSTITUTED,2,2-DIARYL-4-PIPERIDINOBUTYRAMIDES AND SALTS THEREOF AND THEIR PREPARATION
U.S.S.R.	845776	METHOD OF PREPARING 2,2-DIARYL-4-(4'-OXYPIPERIDINO)-BUTYLAMIDES OR THEIR SALTS
Poland	81548
Austria	312606
Japan	S5817749

Supplementary Protection Certificates for IMODIUM A-D

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0428296	SPC/GB98/013	United Kingdom		PRODUCT NAME: LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE; REGISTERED: UK 00242/0314 19970923

Market Dynamics and Financial Trajectory for IMODIUM A-D

Last updated: January 30, 2026

Executive Summary

Imodium A-D (loperamide hydrochloride) remains a key over-the-counter (OTC) medication for acute diarrhea management. Its market continues to evolve amid increasing global demand for rapid, effective symptomatic relief and the expansion of OTC markets in emerging economies. This report analyzes the current market landscape, competitive positioning, regulatory influences, and future financial trajectories for Imodium A-D from 2023 onward.

---

Introduction

Imodium A-D, a product of Johnson & Johnson, was introduced in the 1970s as an OTC antidiarrheal agent. It primarily functions as a peripheral μ-opioid receptor agonist, reducing intestinal motility. Despite its longstanding market presence, Imodium A-D faces evolving dynamics driven by regulatory scrutiny, competitive alternatives, and shifting consumer preferences. This document assesses these influences, alongside projected revenues, growth rates, and strategic considerations.

---

1. Market Overview

1.1 Global Market Size and Growth

Year	Global Market Value (USD billion)	CAGR (2018-2023)	Predicted (2023-2028) CAGR	Key Drivers
2018	1.4	5.2%	4.8%	Increasing prevalence of infectious diarrhea; OTC availability
2023	1.75	NA	4.5%	Rising awareness, expanding OTC markets, healthcare access
2028 (proj.)	2.20	NA		Demographics, global health initiatives

Source: Market Research Future [1], Grand View Research [2]

1.2 Regional Market Distribution

Region	Market Share (%)	Key Factors
North America	45	High OTC OTC penetration; developed healthcare systems
Europe	25	Stringent regulations; focus on OTC accessibility
Asia-Pacific	20	Growing middle class; rising awareness; regulatory shifts in China and India
Rest of World	10	Emerging markets; expanding OTC distribution

1.3 Market Segmentation by Application

Segments	Description	Market Share (%)
OTC diarrhea relief	Primary	80
Prescription-only drugs	Secondary	20

---

2. Competitive Landscape

2.1 Major Competitors

Company	Product Name	Market Share (%)	Key Differentiators
Johnson & Johnson	Imodium A-D	~60	Global distribution, brand recognition
Reckitt Benckiser	Loperamide (generic)	~20	Cost competitiveness
Mylan	Loperamide (generic)	~10	Competitive pricing
Others	Various generics	~10	Regional players

Note: Exact market shares are estimated based on industry reports [3]

2.2 Competitive Strategies

• Brand Loyalty: Johnson & Johnson maintains significant consumer trust.
• Pricing Strategies: Generics challenge branded products primarily on price.
• Product Formulations: Introducing pediatric and extended-release formulations.
• Market Expansion: Targeting low- and middle-income countries through partnerships.

2.3 Patent and Regulatory Considerations

• Patent expiration: The original patent expired in 2004, leading to broad generic adoption.
• Regulatory policies: Variations in OTC classification across regions affect pricing and accessibility.

---

3. Regulatory and Policy Impacts

3.1 Regulatory Environment

• United States:
  • FDA classifies Imodium A-D as OTC since 1974.
  • Recent scrutiny over misuse and opioid dependence concerns led to enhanced consumer warnings.
• European Union:
  • Approved as OTC; regulatory focus on safety in vulnerable populations.
• Asia-Pacific:
  • Regulatory landscapes vary; some markets pending OTC approval or reclassification initiatives.

3.2 Policy Trends and Their Effects

Trend	Effect	Source
Increased safety warnings	Slight market contraction	[4]
Encouragement of OTC access for diarrhea in emerging markets	Market expansion	[5]
Reclassification efforts (e.g., China, India)	Potential for OTC growth	[6]

---

4. Financial Trajectory Analysis

4.1 Revenue Breakdown and Trends

Year	Estimated Revenue (USD million)	Notes
2022	$450	Stable with moderate growth; slight decline in developed markets due to generic competition
2023	$470	Slight recovery driven by emerging market penetration
2024-2028 (Projected CAGR 4.8%)	Increasing to ~$600	Expanded OTC access, formulation innovations, demographic shifts

4.2 Revenue Drivers

• Market Expansion: Entry into new regional markets.
• Product Innovation: Development of new formulations.
• Regulatory Actions: Favorable reclassification increases accessibility.
• Consumer Preferences: Preference for OTC, convenience, and home-based care.

4.3 Risks and Challenges

• Regulatory Restrictions: Potential reclassification or stricter warnings.
• Market Saturation: Mature markets may limit growth.
• Generic Competition: Price erosion pressure.
• Misuse Concerns: Opioid dependency risks influencing policy.

---

5. Comparison with Similar OTC Antidiarrheals

Product	Active Ingredient	OTC Status	Market Share (%)	Key Differentiator
Imodium A-D	Loperamide hydrochloride	OTC	~60	Proven efficacy, global distribution
Pepto-Bismol	Bismuth subsalicylate	OTC	~25	Dual action (antisecretory, antimicrobial)
Kaopectate	Attapulgite	OTC	~10	Tied to multiple formulations

Implication: Imodium A-D maintains dominance but faces rising competitive pressure from alternative formulations.

---

6. Strategic Outlook and Future Opportunities

Opportunity	Description	Expected Impact
Geographic Diversification	Strengthening presence in Africa, Southeast Asia	Incremental revenue growth
Formulation Innovations	Pediatric, extended-release, combination products	Market differentiation
Digital and E-commerce Expansion	Direct-to-consumer platforms	Increased access and brand loyalty
Regulatory Advocacy	Streamlining OTC approval processes	Accelerated market entry

---

7. Key Challenges and Mitigation Strategies

Challenge	Mitigation Strategy
Regulatory Reclassification	Proactive engagement with authorities
Price Erosion	Focus on value-added formulations
Consumer Education	Campaigns on safe use and indications
Competition from Generics	Brand reinforcement, quality assurance

---

Key Takeaways

• Stable Market Position: Imodium A-D commands a significant share of the global OTC antidiarrheal market due to brand recognition and widespread distribution.
• Growth Drivers: Emerging markets, formulation innovation, and regulatory reclassification efforts are critical growth levers.
• Competitive Pressure: Generics and alternative therapies require differentiation through quality, formulations, and consumer trust.
• Regulatory Environment: Vigilance over safety warnings and policy shifts is essential to maintaining market access.
• Financial Outlook: Expect a compound annual growth rate of approximately 4.8% from 2023-2028, with revenues reaching around USD 600 million by 2028.

---

FAQs

1. How does regulatory scrutiny impact Imodium A-D's market?
Regulatory agencies, particularly the FDA and EMA, have implemented safety warnings due to concerns over misuse and dependency. While these measures modestly temper sales, proactive engagement and formulation adjustments can mitigate adverse impacts.

2. What regional markets are most promising for Imodium A-D expansion?
Emerging markets in Asia-Pacific, Africa, and Latin America offer substantial growth potential owing to expanding OTC access and increasing awareness of diarrhea management.

3. How does the rise of generics affect Imodium A-D’s profitability?
Generics exert price pressure, but brand strength, safety perceptions, and formulations help maintain margins. Diversification and innovation remain essential.

4. What are the prospects of reformulation strategies?
Developing pediatric formulations, extended-release variants, or combination products can create differentiation, address unmet needs, and drive growth.

5. How do consumer behaviors influence future market dynamics?
Preference toward OTC medications, home healthcare, and digital health platforms align with Imodium A-D’s distribution strategies, supporting ongoing adoption.

---

References

1. Market Research Future. "Over-the-Counter (OTC) Drugs Market." 2021.
2. Grand View Research. "Diarrheal Disease Treatment Market Analysis." 2022.
3. IQVIA. "Global OTC Sales Data." 2022.
4. U.S. Food and Drug Administration. "Labeling and safety warning updates for Loperamide." 2021.
5. WHO. "Strategies to improve access to OTC medications in low-income countries." 2020.
6. Indian Ministry of Health. "OTC Regulations and Policy Trends." 2022.